US 11,891,432 B2
Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
Katja Fink, Singapore (SG); Cheng-I Wang, Singapore (SG); Lisa Fong Poh Ng, Singapore (SG); Laurent Renia, Singapore (SG); Zenjiro Sampei, Gotemba (JP); and Xing'er Christine Xoo, Singapore (SG)
Assigned to Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP); and Agency for Science, Technology & Research, Singapore (SG)
Appl. No. 16/980,611
Filed by Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP); and Agency for Science, Technology & Research, Singapore (SG)
PCT Filed Mar. 15, 2019, PCT No. PCT/SG2019/050145
§ 371(c)(1), (2) Date Sep. 14, 2020,
PCT Pub. No. WO2019/177543, PCT Pub. Date Sep. 19, 2019.
Claims priority of application No. 10201802164Y (SG), filed on Mar. 15, 2018.
Prior Publication US 2021/0017256 A1, Jan. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/10 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/1081 (2013.01) [A61P 31/14 (2018.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/567 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 2 Claims
 
1. A method for treating Zika virus infection, comprising administering an antibody that binds to Zika virus, wherein the antibody comprises:
a VH comprising the amino acid sequence of SEQ ID NO: 6,
a human IgG1 CH comprising the amino acid sequence of SEQ ID NO: 59,
a VL comprising the amino acid sequence of SEQ ID NO: 7, and
a human CL.